Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.58 |
| ▸ | DPP4 | P27487 | 5/20 | 0.56 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | TLR4 | O00206 | 1/20 | 0.54 |
| ▸ | CPB1 | P15086 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807313 | 1.00 | ALDH1A1 (0.65) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL10188288 | 1.00 | ALDH1A1 (0.65) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL8548058 | 1.00 | ALDH1A1 (0.65) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL2621442 | 1.00 | ALDH1A1 (0.65) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL6854711 | 0.91 | ALDH1A1 (0.67) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL31206191 | 0.91 | ALDH1A1 (0.67) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL15221619 | 0.91 | ALDH1A1 (0.65) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL9470730 | 0.91 | ALDH1A1 (0.65) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL15221598 | 0.91 | ALDH1A1 (0.65) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL24920336 | 0.90 | ALDH1A1 (0.61) | ALDH1A1GAATSHREPHX1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872502-B1 | NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2016-08-24 | — | — | EP | disclosed |
| US-20160200741-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200741-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-07-14 | — | — | US | disclosed |
| US-9206191-B2 | Indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206191-B2 | Indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150158879-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150158879-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-06-11 | — | — | US | disclosed |
| WO-2014009302-A1 | NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-16 | — | — | WO | disclosed |
| US-20070063196-A1 | Light emitting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158879-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | ADORA3, ADORA1, BRS3 | ALDH1A1 943/4885GAA 3310/4885TSHR 856/4885 |
| US-20160200741-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | ADORA3, ADORA1, BRS3 | ALDH1A1 943/4885GAA 3310/4885TSHR 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.